A prostate secretory protein94-derived synthetic peptide PCK3145 inhibits VEGF signalling in endothelial cells: Implication in tumor angiogenesis

International Journal of Cancer

Volumn 118, Issue 9, 2006, Pages 2350-2358

  Lamy, Sylvie ^a   Ruiz, Marcia T ^b   Wisniewski, Jan ^b   Garde, Seema ^b   Rabbani, Shafaat A ^c   Panchal, Chandra ^b   Wu, Jinzi J ^b   Annabi, Borhane ^d  

^a UNIVERSITY OF MONTREAL   (Canada)

^b INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

Author keywords

ERK; Prostate cancer; Tumor angiogenesis; Tyrosine kinase inhibitor; VEGF receptor

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ANGIOGENESIS INHIBITOR; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE; PCK 3145; PROSTATE SECRETORY PROTEIN 94 DERIVED SYNTHETIC PEPTIDE; PROSTATIC SECRETORY PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2; VATALANIB;

AMINO ACID ANALYSIS; ANGIOGENESIS; ARTICLE; CANCER INHIBITION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; HORMONAL CARCINOGENESIS; HUMAN; HUMAN CELL; IN VIVO STUDY; MOLECULAR MECHANICS; NEOVASCULARIZATION (PATHOLOGY); PEPTIDE SYNTHESIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN ANALYSIS; TUMOR GROWTH;

ANIMALS; CELL CULTURE TECHNIQUES; ENDOTHELIAL CELLS; MALE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MUSCLE, SMOOTH; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROSTATIC SECRETORY PROTEINS; RATS; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33645669658     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21615     Document Type: Article

References (53)

1. Yang JP, Finkelman MA, Clarke MW. Detection of PSP94 and its specific binding sites in ihe prostate adenocarcinoma cell line LNCaP. J Urol 1998;160:2240-4.
2. Abrahamsson PA, Lilja H. Three predominant prostatic proteins. Andrologia 1990;22:122-31.
3. Sakai H, Tsurusaki T, Kanda S, Koji T, Xuan JW, Saito Y. Prognostic significance of β-microseminoprotein mRNA expression in prostate cancer. Prostate 1999;38:278-84.
4. Shukeir N, Arakelian A, Kadhim S, Garde S, Rabbani SA. Prostate secretory protein PSP94 decreases tumor growth and hypercalcemia of malignancy in a syngenic in vivo model of prostate cancer. Cancer Res 2003;63:2072-8.
5. Shukeir N, Arakelian A, Chen G, Garde S, Ruiz M, Panchal C, Rabbani SA. A synthetic 15-mer peptide (PCK3145) derived from prostate secretory protein can reduce tumor growth, experimental skeletal metastases, and malignancy-associated hypercalcemia. Cancer Res 2004;64:5370-7.
6. Hawkins R, Panchal C, Dulude H, Cowan R, Armstrong A, Fenemore J, Daigneault L. A multiple ascending dose, open-label, phase IIa study evaluating the safety and tolerability of PCK3145 administered intravenously in patients with metastatic hormone refractory prostate cancer (HRPC). J Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 22(Suppl 14):4636.
7. Daigneault L, Dulude H, Panchal C, Garde S, Armstrong A, Cowan R, Hawkins R. Evaluation of biological activity of PCK3145 in metastatic hormone resistant prostatic cancer (HRPC) using serum markers. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 22(Suppl 14):4692.
8. Fidler IJ. Modulation of the organ microenvironment for the treatment of cancer metastasis. J Natl Cancer Inst 1995; 1588-92.
9. Folkman MJ. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992;3:65-71.
10. Auerbach W, Auerbach R. Angiogenesis inhibition: a review. Pharmacol Ther 1994;63:265-311.
11. Auerbach R, Lewis R, Shinners B, Kubai, Akhtar N. Angiogenesis assays: a critical overview. Clin Chem 2003;49:32-40.
12. Lutsenko SV, Kiselev SM, Severin SE. Molecular mechanisms of tumor angiogenesis. Biochemistry (Moscow) 2003;68:286-300.
13. Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 1995;36:169-80.
14. Campbell SC. Advances in angiogenesis research: relevance to urological oncology. J Urol 1997;158:1663-74.
15. Bettencourt MC, Bauer JJ, Sesterhenn IA, Connelly RR, Moul JW. CD 34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. J Urol 1998;160:459-65.
16. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 2001;280: C1358-66.
17. Jackson MW, Bentel JM, Tilley WD. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol 1997;157:2323-8.
18. Harper ME, Glynne-Jones E, Goddard L, Thurston VJ, Griffiths K. Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells. Br J Cancer 1996;74:910-6.
19. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, Kreutzer DL. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J Urol 1997;157:2329-33.
20. Levine AC, Liu XH, Greenberg PD, Eliashvili M, Schiff JD, Aaronson SA, Holland JF, Kirschenbaum A. Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts. Endocrinology 1998;139:4672-8.
21. Matsumoto T, Claesson-Welsh L. VEGF receptor signal transduction. Sci STKE 2001;2001:RE21.
22. Huss WJ, Hanrahan CF, Barrios RJ, Simons JW, Greenberg NM. Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res 2001;61:2736-43.
23. Durocher Y, Perret S, Kamen A. High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res 2002;30:E9.
24. Pham PL, Perret S, Doan HC, Cass B, St-Laurent G, Kamen A, Durocher Y. Large-scale transient transfection of serum-free suspension-growing HEK293 EBNA1 cells: peptone additives improve cell growth and transfection efficiency. Biotechnol Bioeng 2003;84:332-42.
25. Chen G, Shukeir N, Potti A, Sircar K, Aprikian A, Goltzman D, Rabbani SA. Upregulation of Wnt-1 and β-catenin production in advanced metastatic human prostate cancer: potential pathogenetic and prognostic implications. Cancer 2004;101:1345-56.
26. Annabi B, Lee YT, Martel C, Pilorget A, Bahary JP, Béliveau R. Radiation induced-tubulogenesis in endothelial cells is antagonized by the antiangiogenic properties of green tea polyphenol (-) epigallocatechin-3- gallate. Cancer Biol Ther 2003;2:642-9.
27. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 1995;92:7686-9.
28. Fisher C, Gilbertson-Beadling S, Powers EA, Petzold G, Poorman R, Mitchell MA. Interstitial collagenase is required for angiogenesis in vitro. Dev Biol 1994;162:499-4.
29. Schnaper HW, Grant DS, Stetler-Stevenson WG, Fridman R, D'Orazi G, Murphy AN, Bird RE, Hoythya M, Fuerst TR, French DL. Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitro. J Cell Physiol 1993;156:235-46.
30. Genersch E, Haye§ K, Neuenfeld Y, Haller H. Sustained ERK phosphorylation is necessary but not sufficient for MMP-9 regulation in endothelial cells: involvement of Ras-dependent and -independent pathways. J. Cell Sci. 2000;113:4319-30.
31. Chi KN, Cleave ME. Antisense approaches in prostate cancer. Expert Opin Biol Ther 2004;4:927-36.
32. Blackledge G. Growth factor receptor tyrosine kinase inhibitors; clinical development and potential for prostate cancer therapy. J Urol 2003;170:577-83.
33. Schlaeppi JM. Wood, targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors. Cancer Metastasis Rev 1999;18:473-81.
34. Kroll J, Waltenberger J. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J Biol Chem 1997;272:32521-7.
35. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. J Biol Chem 1998;273:30336-43.
36. Fingleton B, Matrisian LM. Matrix metalloproteinases as targets for therapy in Kaposi sarcoma. Curr Opin Oncol 2001;13:368-73.
37. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: bioloaic activity and clinical implications. J Clin Oncol 2000;18:1135-49.
38. van Moorselaar RJ, Voest EE. Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches. Mol Cell Endocrinol 2002;197:239-50.
39. Arakawa A, Soh S, Chakraborty S, Scardino PT, Wheeler TM. Prognostic significance of angiogenesis in clinically localized prostate cancer (staining for Factor VIII-related antigen and CD34 Antigen. Prostate Cancer Prostatic Dis 1997;1:32-8.
40. Bettencourt MC, Bauer JJ, Sesterhenn IA, Connelly RR, Moul JW. CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. J Urol 1998;160:459-65.
41. Bono AV, Celato N, Cova V, Salvadore M, Chinetti S, Novario R. Microvessel density in prostate carcinoma. Prostate Cancer Proslatic Dis 2002;5:123-7.
42. Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP, Menger MD, Ullrich A, Vajkoczy P. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004;18:338-40.
43. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111:1287-95.
44. Hirschi KK, Rohovsky SA, D'Amore PA. PDGF, TGF-beta, and heterotypic cell-cell interactions mediate endothelial cell-induced recruitment of 10T1/2 cells and their differentiation to a smooth muscle fate. J Cell Biol 1998;141:805-14.
45. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6:389-95.
46. Benjamin LE, Memo I, Keshet E. A plasticity window for blood vessel remodeling is defined bu pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998;125:1591-8.
47. Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, Schlessinger J, Ullrich A, Hubbard SR, Blake RA, Fong TA, Strawn LM, et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 2000;60:4152-60.
48. Hiratsuka S, Nakamura K, Iwai S, Murakami M, Itoh T, Kijima H, Shipley JM, Senior RM, Shibuya M. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2002;2:289-300.
49. Pomeroy M, Moriarty M. Clinical significance of cellular resistance in tumours to cytotoxic chemotherapy and radiotherapy. Cytotechnology 1993;12:385-91.
50. Beer TM, Bubalo JS. Complications of chemotherapy for prostate cancer. Semin Urol Oncol 2001;19:222-30.
51. Taraboletti G, Giavazzi R. Modelling approaches for angiogenesis. Eur J Cancer. 2004;40:881-9.
52. Blackledge G. Growth factor receptor tyrosine kinase inhibitors; clinical development and potential for prostate cancer therapy. J Urol 170: S77-83, 2003.
53. Gingras D, Lamy S, Béliveau R. Tyrosine phosphorylation of the vascular endothelial growth factor receptor-2 (VEGFR-2) is modulated by Rho proteins. Biochem J 2000;348:273-80.